Fitzsimons Innovation Community
Fitzsimon_menu

Find out what's happening on campus and across the industry.

Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.

Blog
LIGHT LABS Celebrates 10 Years of Success at Fitzsimons Innovation Community
April 23, 2024
Blog
Fitzsimons Innovation Community Celebrates Women Leaders
March 26, 2024
Blog
Fitzsimons Innovation Community Partners with the Colorado Hub for Health Impact Campaign
February 27, 2024
Innosphere Ventures Fund Announces Major Investment in GelSana to Revolutionize Advanced Wound Care
News | Nov 30, 2023

Innosphere Ventures Fund Announces Major Investment in GelSana to Revolutionize Advanced Wound Care

Fort Collins, CO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures Fund is thrilled to announce a significant follow-on investment in GelSana, a groundbreaking company in the advanced wound care industry. GelSana has secured $3.1M to date in both dilutive and non-dilutive funding for its innovative hydrogel technology.

Changing the Game for a Thriving Local Economy
Blog | Nov 28, 2023

Changing the Game for a Thriving Local Economy

Fitzsimons Innovation Community awarded for work in economic vitality. Last month, the Adams County Regional Economic Partnership (AC-REP) hosted its second annual Gamechangers Awards event. This event celebrates organizations in the region that have had a positive impact on the Adams County economy, and Fitzsimons Innovation Community was honored to be among the recipients.

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain
News | Nov 01, 2023

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain

Focusing on non-addictive treatments for chronic pain and addiction, Lohocla Research Corporation gets the go-ahead for first-in-human trials of their first-in-class therapeutic for chronic pain syndromes.

© 2024

 Fitzsimons Innovation Community